SALT LAKE CITY, Sept. 07, 2016 (GLOBE NEWSWIRE) -- Myriad RBM, Inc., a wholly owned subsidiary of Myriad
Genetics, Inc. (NASDAQ:MYGN) a global leader in personalized medicine, announced today that researchers from the Institut Pasteur
have published new landmark research from the Milieu Interieur Project relating to the ability to perform standardized
transcriptome profiling based upon a variety of immune stimuli in the August issue of Cell Reports. The study looked at
the expression levels of different genes in 25 subjects following TruCulture incubation with twenty clinically relevant immune
system stimulants. The research demonstrated that expression levels from as few as 44 of the 572 genes tested could segregate
responses from the various stimuli and reveal variations in immune response.
"We are excited by the results of this study which demonstrated that a relatively small subset of gene
expression targets could explain the variability in immune response to different immune stimuli seen among patients," said Matthew
Albert, co-coordinator of Milieu Interieur and director of the Immunobioology of Dendritic Cells Unit at the Institut Pasteur. "The
ability of TruCulture to perform this analysis in an ex-vivo environment is truly unique making it an invaluable tool for assessing
potential biomarkers relevant to immune response in patients."
To perform the study, the researchers at the Institut Pasteur utilized Myriad RBM’s TruCulture technology which
is a proprietary blood collection and culturing system that allows researchers to perform ex-vivo immune system analysis. Unlike
the current laboratory-based methods, TruCulture is deployed at the site of collection and therefore avoids variability from
shipping and complex processing as well as the expense of a cell culture facility and staff.
"We are increasingly excited around the prospects for TruCulture both for use in pharmaceutical research as well
as for potential future diagnostic products," said Ralph McDade, president of Myriad RBM. "We are actively pursuing several
research collaborations to develop TruCulture as a novel diagnostic in cancer immunotherapy, autoimmune disorders, mental illness
and vaccine response."
This research builds upon earlier work at the Institut Pasteur that looked at the ability of TruCulture to
accurately and reproducibly measure protein based cytokine responses in patient samples relative to different immune stimuli. The
approaches and learnings from this study and previous studies will now be utilized in over 1,000 healthy donors with the Milieu
Interieur cohort that will evaluate how different factors such as age, gender, environment, lifestyle, and genetics contribute to
variable immune responses.
About Institut Pasteur and the Milieu Interieur Project
The Institut Pasteur, a private foundation with officially recognized charitable status set up by Louis Pasteur
in 1887, is today an internationally renowned center for biomedical research with a network of 33 institutes worldwide. In the
pursuit of its mission to prevent and fight against diseases in France and throughout the world, the Institut Pasteur operates in
four main areas: scientific and medical research, public health and health monitoring, teaching, and business development and
technology transfer. www.pasteur.fr/en
The Milieu Interieur project is a population-based study supported by the French National Ministry of Research
and coordinated by the Institut Pasteur, Paris. The goal of Milieu Interieur is to characterize the immune phenotypes of 1,000
healthy subjects in response to 32 complex immune stimulants. Responses to these stimuli in TruCulture are being assessed using
advanced cellular, nucleic acid, proteomic and metabolic assay technologies. For more information visit: www.milieuinterieur.fr/en
About Myriad Genetics
Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor
transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular
diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease
progression and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly
improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and
expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and
increasing the revenue contribution from international markets. For more information on how Myriad is making a difference,
please visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, EndoPredict, myPath, myRisk, Myriad
myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, Vectra and Prolaris are
trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign
countries. MYGN-F, MYGN-G
Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation
Reform Act of 1995, including statements relating to use of TruCulture as a tool for assessing potential biomarkers relevant to
immune response in patients; the use of TruCulture in pharmaceutical research as well as for potential future diagnostic products;
to potential research collaborations to develop TruCulture as a novel diagnostic in cancer immunotherapy, autoimmune disorders,
mental illness and vaccine response; and the Company’s strategic directives under the caption “About Myriad Genetics.” These
“forward-looking statements” are based on management’s current expectations of future events and are subject to a number of risks
and uncertainties that could cause actual results to differ materially and adversely from those described or implied in the
forward-looking statements. These risks include, but are not limited to: the risk that sales and profit margins of our existing
molecular diagnostic tests and pharmaceutical and clinical services may decline or will not continue to increase at historical
rates; risks related to our ability to transition from our existing product portfolio to our new tests; risks related to changes in
the governmental or private insurers’ reimbursement levels for our tests or our ability to obtain reimbursement for our new tests
at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and
services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and
pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for
our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue
outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical
and clinical services tests and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to
delays or other problems with operating our laboratory testing facilities; risks related to public concern over our genetic testing
in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign
countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to
obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks
related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or
acquire, including but not limited to our acquisition of a healthcare clinic in Germany; risks related to our projections about the
potential market opportunity for our products; the risk that we or our licensors may be unable to protect or that third parties
will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the
validity of our patents; risks related to changes in intellectual property laws covering our molecular diagnostic tests and
pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme
Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and
competitive technologies and regulations in the United States and internationally; and other factors discussed under the heading
“Risk Factors” contained in Item 1A of our Annual report on Form 10-K for the fiscal year ended June 30, 2016, which has been filed
with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly
Reports on Form 10-Q or Current Reports on Form 8-K.
Media Contact: Ron Rogers (908) 285-0248 rrogers@myriad.com Investor Contact: Scott Gleason (801) 584-1143 sgleason@myriad.com